Oncocyte Corporation
OCX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$117.6M
Close$
$-1.65
151.7% downside
Current Fair Value
151.7% downsideOvervalued by 151.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $117.60 Million |
|---|---|
| Enterprise Value | $102.47 Million |
| Earnings per Share | $-1.65 |
| Beta | 0.99 |
| Outstanding Shares | 36,750,000 |
Return
| Return on Equity | 231.74% |
|---|---|
| Return on Assets | -167.64% |
| Return on Invested Capital | -261.39% |
Valuation & Multiples
| P/E Ratio | -1.95 |
|---|---|
| PEG | -12.5 |
| Price to Sales | - |
| Price to Book Ratio | -3.2 |
| Enterprise Value to Revenue | 61.36 |
| Enterprise Value to EBIT | -2.05 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | -0.12 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 10, 2025
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About OncoCyte Corp
57 employees
CEO: Joshua Riggs
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the Uni...